<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of defects in intrinsic and innate immunity (category VI inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of defects in intrinsic and innate immunity (category VI inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of defects in intrinsic and innate immunity (category VI inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">Affected cells</td> <td class="subtitle1">Affected function</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Mendelian susceptibility to mycobacterial disease (MSMD)</td> </tr> <tr> <td class="indent1">IL-12 and IL-23 receptor beta 1 chain deficiency</td> <td>Interleukin 12 receptor subunit beta 1 (<em>IL12RB1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601604" target="_blank">601604</a></td> <td>Lymphocytes, NK cells</td> <td>IFN-gamma secretion</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">IL-12p40 (IL-12 and IL-23) deficiency</td> <td>Interleukin 12B (<em>IL12B</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/161561" target="_blank">161561</a></td> <td>Monocytes</td> <td>IFN-gamma secretion</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">IL-12 receptor beta 2 deficiency</td> <td>Interleukin 12 receptor subunit beta 2 (<em>IL12RB2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601642" target="_blank">601642</a></td> <td>Lymphocytes, NK cells</td> <td>IFN-gamma secretion</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">IL-23R deficiency</td> <td>Interleukin 23 receptor (<em>IL23R</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607562" target="_blank">607562</a></td> <td>Lymphocytes, NK cells</td> <td>IFN-gamma secretion</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1" rowspan="2">IFN-gamma receptor 1 deficiency</td> <td rowspan="2">Interferon gamma receptor 1 (<em>IFNGR1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/209950" target="_blank">209950</a></td> <td>Monocytes, lymphocytes</td> <td>IFN-gamma binding and signaling</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td>AD</td> <td><a href="https://www.omim.org/entry/615978" target="_blank">615978</a></td> <td>Monocytes, lymphocytes</td> <td>IFN-gamma binding and signaling</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">IFN-gamma receptor 2 deficiency</td> <td>Interferon gamma receptor 2 (<em>IFNGR2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147569" target="_blank">147569</a></td> <td>Monocytes, lymphocytes</td> <td>IFN-gamma signaling</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">STAT1 deficiency</td> <td>Signal transducer and activator of transcription 1 (<em>STAT1</em>)</td> <td>AD LOF</td> <td><a href="https://www.omim.org/entry/614892" target="_blank">614892</a></td> <td>Monocytes, lymphocytes</td> <td>IFN-gamma signaling</td> <td>Susceptibility to mycobacteria and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">Macrophage gp91 phox deficiency</td> <td>Cytochrome b-245 beta chain (<em>CYBB</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300645" target="_blank">300645</a></td> <td>Macrophage only</td> <td>Killing (faulty O<sub>2</sub><sup>+</sup>) production</td> <td>Isolated susceptibility to mycobacteria</td> </tr> <tr> <td class="indent1" rowspan="2">IRF8 deficiency</td> <td rowspan="2">Interferon regulatory factor 8 (<em>IRF8</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/614893" target="_blank">614893</a></td> <td>Monocytes, lymphocytes</td> <td>Impaired development of cDCs and Th1<sup>+</sup> cells</td> <td>Susceptibility to mycobacterial</td> </tr> <tr> <td>AR</td> <td><a href="https://www.omim.org/entry/226990" target="_blank">226990</a></td> <td>Monocytes</td> <td>Lack of circulating monocytes and DCs; reduced NK cell numbers and function reported in some patients</td> <td>Susceptibility to mycobacterial and multiple other infectious agents including EBV</td> </tr> <tr> <td class="indent1">SPPL2a deficiency</td> <td>Signal peptide peptidase-like 2A (<em>SPPL2A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/608238" target="_blank">608238</a></td> <td>Monocytes, lymphocytes</td> <td>Impaired development of cDCs and Th1<sup>+</sup> cells</td> <td>Susceptibility to mycobacterial and <em>Salmonella</em></td> </tr> <tr> <td class="indent1">Tyk2 deficiency</td> <td>Tyrosine kinase 2 (<em>TYK2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/611521" target="_blank">611521</a></td> <td>Monocytes, lymphocytes</td> <td>Impaired cellular responses to IL-10, IL-12, IL-23, and type I IFNs</td> <td>Susceptibility to intracellular bacteria (mycobacteria,<em> Salmonella</em>) and viruses</td> </tr> <tr> <td class="indent1">P1104A TYK2 homozygosity</td> <td>Tyrosine kinase 2 (<em>TYK2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/176941" target="_blank">176941</a></td> <td>Lymphocytes</td> <td>Impaired cellular response to IL-23</td> <td>MSMD or tuberculosis</td> </tr> <tr> <td class="indent1">ISG15 deficiency</td> <td>ISG15 ubiquitin-like modifier (<em>ISG15</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147571" target="_blank">147571</a></td> <td> </td> <td>IFN-gamma production defect</td> <td>Susceptibility to mycobacteria (BCG), brain calcification</td> </tr> <tr> <td class="indent1">ROR-gamma-t deficiency</td> <td>RAR-related orphan receptor C (<em>RORC</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602943" target="_blank">602943</a></td> <td>Lymphocytes, NK cells</td> <td>Lack of functional ROR-gamma-T protein; IFN-gamma production defect; complete absence of IL-17A/F-producing T cells</td> <td>Susceptibility to mycobacteria and <em>Candida</em></td> </tr> <tr> <td class="indent1">JAK1 deficiency</td> <td>Janus kinase 1 (<em>JAK1</em>)</td> <td>AR LOF</td> <td><a href="https://www.omim.org/entry/147795" target="_blank">147795</a></td> <td>Neutrophils, lymphocytes</td> <td>Reduced JAK1 activation to cytokines; reduced IFN-gamma production</td> <td>Susceptibility to mycobacteria and viruses, urothelial carcinoma</td> </tr> <tr> <td class="indent1">T-bet deficiency</td> <td>T-box transcription factor 21 (<em>TBX21</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619630" target="_blank">619630</a></td> <td>Lymphocytes</td> <td>Decreased IFN-gamma and TNF-alpha production by gamma-delta T cells, MAIT cells, iNKT cells, NK cells, and CD4<sup>+</sup> T cells</td> <td>Susceptibility to mycobacteria</td> </tr> <tr> <td class="indent1">IFN-gamma deficiency</td> <td>Interferon gamma (<em>IFNG</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618963" target="_blank">618963</a></td> <td>Lymphocytes</td> <td>No IFN-gamma production by patient T and NK cells</td> <td>Susceptibility to mycobacteria</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Epidermodysplasia verruciformis (HPV)</td> </tr> <tr> <td class="indent1">EVER1 deficiency</td> <td>Transmembrane channel-like 6 (<em>TMC6</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605828" target="_blank">605828</a></td> <td>Keratinocytes</td> <td>EVER1, EVER2, and CIB1 form a complex in keratinocytes</td> <td>HPV (group B1) infections and cancer of the skin (typical epidermodysplasia verruciformis)</td> </tr> <tr> <td class="indent1">EVER2 deficiency</td> <td>Transmembrane channel-like 8 (<em>TMC8</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605829" target="_blank">605829</a></td> <td>Keratinocytes</td> <td>EVER1, EVER2, and CIB1 form a complex in keratinocytes</td> <td>HPV (group B1) infections and cancer of the skin (typical epidermodysplasia verruciformis)</td> </tr> <tr> <td class="indent1">CIB1 deficiency</td> <td>Calcium and integrin binding 1 (<em>CIB1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618267" target="_blank">618267</a></td> <td>Keratinocytes</td> <td>EVER1, EVER2, and CIB1 form a complex in keratinocytes</td> <td>HPV (group B1) infections and cancer of the skin (typical epidermodysplasia verruciformis)</td> </tr> <tr> <td class="indent1">WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) syndrome</td> <td>C-X-C motif chemokine receptor 4 (<em>CXCR4</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/162643" target="_blank">162643</a></td> <td>Leukocytes</td> <td>Increased response of the CXCR4 chemokine receptor to its ligand CXCL12 (SDF-1)</td> <td>Warts (HPV) infection, neutropenia, low B cell number, hypogammaglobulinemia</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Predisposition to severe viral infection</td> </tr> <tr> <td class="indent1">STAT1 deficiency</td> <td>Signal transducer and activator of transcription 1 (<em>STAT1</em>)</td> <td>AR LOF</td> <td><a href="https://www.omim.org/entry/600555" target="_blank">600555</a></td> <td>Leukocytes and other cells</td> <td>STAT1-dependent IFN-alpha/beta, gamma, and delta responses</td> <td>Severe viral infections, mycobacterial infection</td> </tr> <tr> <td class="indent1">STAT2 deficiency</td> <td>Signal transducer and activator of transcription 2 (<em>STAT2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/600556" target="_blank">600556</a></td> <td>Leukocytes and other cells</td> <td>STAT2-dependent IFN-alpha/beta and delta responses</td> <td>Severe viral infections (disseminated vaccine-strain measles)</td> </tr> <tr> <td class="indent1">IRF9 deficiency</td> <td>Interferon regulatory factor 9 (<em>IRF9</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147574" target="_blank">147574</a></td> <td>Leukocytes and other cells</td> <td>IRF9- and ISGF3-dependent IFN-alpha/beta and delta responses</td> <td>Severe influenza disease</td> </tr> <tr> <td class="indent1">IRF7 deficiency</td> <td>Interferon regulatory factor 7 (<em>IRF7</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605047" target="_blank">605047</a></td> <td>Leukocytes, plasmacytoid DCs, nonhematopoietic cells</td> <td>IFN-alpha, beta, and gamma production and IFN-delta production</td> <td>Severe influenza disease</td> </tr> <tr> <td class="indent1">IFNAR1 deficiency</td> <td>Interferon alpha and beta receptor subunit 1 (<em>IFNAR1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/107450" target="_blank">107450</a></td> <td>Leukocytes and other cells</td> <td>IFNAR1-dependent responses to IFN-alpha/beta</td> <td>Severe disease cause by yellow fever vaccine and measles vaccine</td> </tr> <tr> <td class="indent1">IFNAR2 deficiency</td> <td>Interferon alpha and beta receptor subunit 2 (<em>IFNAR2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602376" target="_blank">602376</a></td> <td>Broadly expressed</td> <td>IFNAR2-depnent responses to IFN-alpha/beta</td> <td>Severe viral infections (disseminated vaccine-strain measles, HHV6)</td> </tr> <tr> <td class="indent1">CD16 deficiency</td> <td>Fc gamma receptor IIIa (<em>FCGR3A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/146740" target="_blank">146740</a></td> <td>NK cells</td> <td>Altered NK cell function</td> <td>Severe herpes virus infections, particularly VZV, EBV, and HPV</td> </tr> <tr> <td class="indent1">MDA5 deficiency</td> <td>Interferon induced with helicase C domain 1 (<em>IFIH1</em>)</td> <td>AR LOF</td> <td><a href="https://www.omim.org/entry/606951" target="_blank">606951</a></td> <td>Broadly expressed</td> <td>Viral recognition and IFN induction</td> <td>Rhinovirus and other RNA viruses</td> </tr> <tr> <td class="indent1">NOS2 deficiency</td> <td>Nitric oxide synthase 2 (<em>NOS2</em>)</td> <td>AR</td> <td> </td> <td>Myeloid cells</td> <td>Mutant NOS2 failed to induce nitrous oxide</td> <td>Severe (fatal) susceptibility to CMV-induced disease, pneumocystis pneumonia secondary to CMV, intact responses to infection with other herpes virus (EBV, VZV, HSV)</td> </tr> <tr> <td class="indent1">ZNFX1 deficiency</td> <td>Zinc finger NFX1-type containing 1 (<em>ZNFX1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619644" target="_blank">619644</a></td> <td>Broadly expressed</td> <td>Increased ISG in response to poly I:C</td> <td>Severe infections by RNA/DNA viruses, mycobacteria; early-onset severe inflammation affecting liver, brain, kidneys, lungs; virally triggered inflammatory episodes; hepatosplenomegaly, lymphadenopathy</td> </tr> <tr> <td class="indent1" rowspan="3">RNA polymerase III deficiency</td> <td>RNA polymerase III subunit A (<em>POLR3A</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/614258" target="_blank">614258</a></td> <td>Leukocytes and other cells</td> <td>Impaired viral recognition and IFN induction in response to VZV or poly(I:C)</td> <td>Severe VZV infection</td> </tr> <tr> <td>RNA polymerase III subunit C (<em>POLR3C</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/617454" target="_blank">617454</a></td> <td>Leukocytes and other cells</td> <td>Impaired viral recognition and IFN induction in response to VZV or poly(I:C)</td> <td>Severe VZV infection</td> </tr> <tr> <td>RNA polymerase III subunit F (<em>POLR3F</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/617455" target="_blank">617455</a></td> <td>Leukocytes and other cells</td> <td>Impaired viral recognition and IFN induction in response to VZV or poly(I:C)</td> <td>Severe VZV infection</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Herpes simplex encephalitis (HSE)</td> </tr> <tr> <td class="indent1">TLR3 deficiency</td> <td>Toll-like receptor 3 (<em>TLR3</em>)</td> <td>AD or AR</td> <td><a href="https://www.omim.org/entry/613002" target="_blank">613002</a></td> <td>CNS resident cells and fibroblasts</td> <td>TLR3-dependent IFN-alpha, beta, and gamma response</td> <td>HSV1 encephalitis (incomplete clinical penetrance for all etiologies listed here), severe pulmonary influenza, VZV</td> </tr> <tr> <td class="indent1">UNC93B1 deficiency</td> <td>Unc-93 homolog B1, TLR signaling regulator (<em>UNC93B1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/608204" target="_blank">608204</a></td> <td>CNS resident cells and fibroblasts</td> <td>UNC93B-dependent IFN-alpha, beta, and gamma response</td> <td>HSV1 encephalitis</td> </tr> <tr> <td class="indent1">TRAF3 deficiency</td> <td>TNF receptor-associated factor 3 (<em>TRAF3</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/601896" target="_blank">601896</a></td> <td>CNS resident cells and fibroblasts</td> <td>TRAF3-dependent IFN-alpha, beta, and gamma response</td> <td>HSV1 encephalitis</td> </tr> <tr> <td class="indent1">TRIF deficiency</td> <td>TIR domain-containing adaptor molecule 1 (<em>TICAM1</em>)</td> <td>AD or AR</td> <td><a href="https://www.omim.org/entry/607601" target="_blank">607601</a></td> <td>CNS resident cells and fibroblasts</td> <td>TRIF-dependent IFN-alpha, beta, and gamma response</td> <td>HSV1 encephalitis</td> </tr> <tr> <td class="indent1">TBK1 deficiency</td> <td>TANK-binding kinase 1 (<em>TBK1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/604834" target="_blank">604834</a></td> <td>CNS resident cells and fibroblasts</td> <td>TBK1-dependent IFN-alpha, beta, and gamma response</td> <td>HSV1 encephalitis</td> </tr> <tr> <td class="indent1">IRF3 deficiency</td> <td>Interferon regulatory factor 3 (<em>IRF3</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616532" target="_blank">616532</a></td> <td>CNS resident cells and fibroblasts</td> <td>Low IFN-alpha/beta production in response to HSV1 and decreased IRF3 phosphorylation</td> <td>HSV1 encephalitis</td> </tr> <tr> <td class="indent1">DBR1 deficiency</td> <td>Debranching RNA lariats 1 (<em>DBR1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607024" target="_blank">607024</a></td> <td>CNS resident cells and fibroblasts</td> <td>Impaired production of antiviral IFNs</td> <td>HSE of the brainstem, other viral infections of the brainstem</td> </tr> <tr> <td class="indent1">SNORA31 deficiency</td> <td>Small nucleolar RNA, H/ACA box 31 (<em>SNORA31</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/619396" target="_blank">619396</a></td> <td>CNS resident cells and fibroblasts</td> <td>Impaired production of antiviral IFNs</td> <td>Forebrain HSV1 encephalitis</td> </tr> <tr> <td class="indent1">ATG4A deficiency</td> <td>Autophagy-related 4A cysteine peptidase (<em>ATG4A</em>)</td> <td>AD</td> <td> </td> <td>CNS resident cells and fibroblasts</td> <td>Impaired HSV2-induced autophagy leading to increased viral replication and apoptosis of patient fibroblasts</td> <td>Mollaret meningitis (recurrent lymphocytic meningitis) due to HSV2</td> </tr> <tr> <td class="indent1">MAP1LC3B2 deficiency</td> <td>Microtubule-associated protein 1 light chain 3 beta 2 (<em>MAP1LC3B2</em>)</td> <td>AD</td> <td> </td> <td>CNS resident cells and fibroblasts</td> <td>Impaired HSV2-induced autophagy leading to increased viral replication and apoptosis of patient fibroblasts</td> <td>Mollaret meningitis (recurrent lymphocytic meningitis) due to HSV2</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Predisposition to invasive fungal diseases</td> </tr> <tr> <td class="indent1">CARD9 deficiency</td> <td>Caspase recruitment domain family member 9 (<em>CARD9</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607212" target="_blank">607212</a></td> <td>Mononuclear phagocytes</td> <td>CARD9 signaling pathway</td> <td>Invasive candidiasis infection, deep dermatophytoses, other invasive fungal infections</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Predisposition to mucocutaneous candidiasis</td> </tr> <tr> <td class="indent1">IL-17RA deficiency</td> <td>Interleukin 17 receptor A (<em>IL17RA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605461" target="_blank">605461</a></td> <td>Epithelial cells, fibroblasts, mononuclear phagocytes</td> <td>IL-17RA signaling pathway</td> <td>CMC, folliculitis</td> </tr> <tr> <td class="indent1">IL-17RC deficiency</td> <td>Interleukin 17 receptor C (<em>IL17RC</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610925" target="_blank">610925</a></td> <td>Epithelial cells, fibroblasts, mononuclear phagocytes</td> <td>IL-17RC signaling pathway</td> <td>CMC</td> </tr> <tr> <td class="indent1">IL-17F deficiency</td> <td>Interleukin 17F (<em>IL17F</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/606496" target="_blank">606496</a></td> <td>T cells</td> <td>IL-17F-containing dimers</td> <td>CMC, folliculitis</td> </tr> <tr> <td class="indent1">STAT1 GOF</td> <td>Signal transducer and activator of transcription 1 (<em>STAT1</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/600555" target="_blank">600555</a></td> <td>T cells, B cells, monocytes</td> <td>GOF STAT1 mutations that impair the development of IL-17-producing T cells</td> <td>CMC; various fungal, bacterial, and viral (HSV) infections; autoimmunity (thyroiditis, diabetes, cytopenias); enteropathy</td> </tr> <tr> <td class="indent1">ACT1 deficiency</td> <td>TRAF3 interacting protein 1 (<em>TRAF3IP1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607043" target="_blank">607043</a></td> <td>T cells, fibroblasts</td> <td>Fibroblasts fail to response to IL-17A and IL-17F and their T cells to IL-17E</td> <td>CMC, blepharitis, folliculitis and macroglossia</td> </tr> <tr> <td class="indent1">JNK1 haploinsufficiency</td> <td>Mitogen-activated protein kinase 8 (<em>MAPK8</em>)</td> <td>AD</td> <td> </td> <td>T cells, fibroblasts</td> <td>Decreased Th17 cells ex vivo and in vitro; decreased responses of fibroblasts to IL-17A an IL-17F; decreased c-Jun/ATF2-dependent TGF-beta signalling</td> <td>CMC, connective issue disorder (similar to Ehlers-Danlos syndrome)</td> </tr> <tr> <td class="subtitle2_left" colspan="7">TLR signaling pathway deficiency with bacterial susceptibility</td> </tr> <tr> <td class="indent1">IRAK4 deficiency</td> <td>Interleukin 1 receptor-associated kinase 4 (<em>IRAK4</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606883" target="_blank">606883</a></td> <td>Lymphocytes, granulocytes, monocytes</td> <td>TIR-IRAK4 signaling pathway</td> <td>Bacterial infections (pyogenes)</td> </tr> <tr> <td class="indent1">MyD88 deficiency</td> <td>MYD88 innate immune signal transduction adaptor (<em>MYD88</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602170" target="_blank">602170</a></td> <td>Lymphocytes, granulocytes, monocytes</td> <td>TIR-MyD88 signaling pathway</td> <td>Bacterial infections (pyogenes)</td> </tr> <tr> <td class="indent1">IRAK1 deficiency</td> <td>Interleukin 1 receptor-associated kinase 1 (<em>IRAK1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300283" target="_blank">300283</a></td> <td>Lymphocytes, granulocytes, monocytes</td> <td>TIR-IRAK1 signaling pathway</td> <td>Bacterial infections, XL MECP2 deficiency-related syndrome due to large de novo Xq28 chromosomal deletion encompassing both <em>MECP2</em> and <em>IRAK1</em></td> </tr> <tr> <td class="indent1">TIRAP deficiency</td> <td>TIR domain-containing adaptor protein (<em>TIRAP</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614382" target="_blank">614382</a></td> <td>Lymphocytes, granulocytes, monocytes</td> <td>TIRAP signaling pathway; TLR1/2, TLR2/6, and TLR4 agonists were impaired in the fibroblasts and leukocytes</td> <td>Staphylococcal disease during childhood</td> </tr> <tr> <td class="indent1">TLR7 deficiency</td> <td>Toll-like receptor 7 (<em>TLR7</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/301051" target="_blank">301051</a></td> <td>Lymphocytes, myeloid cells</td> <td>Impaired responses to TLR7 ligands; reduced production of type 1 IFN</td> <td>Severe COVID-19 infection</td> </tr> <tr> <td class="indent1">TLR8 GOF</td> <td>Toll-like receptor 8 (<em>TLR8</em>)</td> <td>XL</td> <td> </td> <td>Myeloid cells</td> <td>Elevated proinflammatory serum cytokines; increased proinflammatory responses of patient myeloid cells to TLR8 agonists; reduced ability of mutant TLR8 to attenuate TLR7 signaling</td> <td>Early-onset severe cytopenias, hepatosplenomegaly, lymphadenopathy; progressive autoinflammatory disease</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Other IEI related to nonhematopoietic tissues</td> </tr> <tr> <td class="indent1" rowspan="2">Isolated congenital asplenia (ICA)</td> <td>Ribosomal protein SA (<em>RPSA</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/271400" target="_blank">271400</a></td> <td>No spleen</td> <td>RPSA encodes ribosomal protein SA, a component of the small subunit of the ribosome</td> <td>Bacteremia (encapsulated bacteria)</td> </tr> <tr> <td>Heme oxygenase 1 (<em>HMOX</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/141250" target="_blank">141250</a></td> <td>Macrophages</td> <td>HMOX regulates iron recycling, and heme-dependent damage occurs</td> <td>Hemolysis, nephritis, inflammation</td> </tr> <tr> <td class="indent1">Trypanosomiasis</td> <td>Apolipoprotein L1 (<em>APOL1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/603743" target="_blank">603743</a></td> <td>Somatic</td> <td>Pore-forming serum protein</td> <td>Trypanosomiasis</td> </tr> <tr> <td class="indent1">Acute liver failure due to NBAS deficiency</td> <td>NBAS subunit of NRZ tethering complex (<em>NBAS</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/608025" target="_blank">608025</a></td> <td>Somatic and hematopoietic</td> <td>ER stress</td> <td>Fever induces liver failure</td> </tr> <tr> <td class="indent1">Acute necrotizing encephalopathy</td> <td>RAN-binding protein 2 (<em>RANBP2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601181" target="_blank">601181</a></td> <td>Ubiquitous expression</td> <td>Nuclear poor</td> <td>Fever induces acute encephalopathy</td> </tr> <tr> <td class="indent1" rowspan="7">Osteopetrosis</td> <td>Chloride voltage-gated channel 7 (<em>CLCN7</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602727" target="_blank">602727</a></td> <td>Osteoclasts</td> <td>Secretory lysosomes</td> <td>Osteopetrosis with hypocalcemia, neurologic features</td> </tr> <tr> <td>Sorting nexin 10 (<em>SNX10</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614780" target="_blank">614780</a></td> <td>Osteoclasts</td> <td>Secretory lysosomes</td> <td>Osteopetrosis with visual impairment</td> </tr> <tr> <td>Osteoclastogenesis-associated transmembrane protein 1 (<em>OSTM1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/607649" target="_blank">607649</a></td> <td>Osteoclasts</td> <td>Secretory lysosomes</td> <td>Osteopetrosis with hypocalcemia, neurologic features</td> </tr> <tr> <td>Pleckstrin homology and RUN domain-containing M1 (<em>PLEKHM1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/611466" target="_blank">611466</a></td> <td>Osteoclasts</td> <td>Secretory lysosomes</td> <td>Osteopetrosis</td> </tr> <tr> <td>T cell immune regulator 1, ATPase H+ transporting V0 subunit a3 (<em>TCIRG1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/604592" target="_blank">604592</a></td> <td>Osteoclasts</td> <td>Secretory lysosomes</td> <td>Osteopetrosis with hypocalcemia</td> </tr> <tr> <td>TNF receptor superfamily member 11a (<em>TNFRSF11A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/603499" target="_blank">603499</a></td> <td>Osteoclasts</td> <td>Osteoclastogenesis</td> <td>Osteopetrosis</td> </tr> <tr> <td>TNF superfamily member 11 (<em>TNFSF11</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602642" target="_blank">602642</a></td> <td>Stromal</td> <td>Osteoclastogenesis</td> <td>Osteopetrosis with severe growth retardation</td> </tr> <tr> <td class="indent1" rowspan="3">Hidradenitis suppurativa</td> <td>Nicastrin (<em>NCSTN</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/605254" target="_blank">605254</a></td> <td>Epidermis</td> <td>Notch signaling/gamma-secretase in hair follicle regulates keratinization</td> <td>Verneuil's disease/hidradenitis suppurativa with acne</td> </tr> <tr> <td>Presenilin (<em>PSEN</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/613737" target="_blank">613737</a></td> <td>Epidermis</td> <td>Notch signaling/gamma-secretase in hair follicle regulates keratinization</td> <td>Verneuil's disease/hidradenitis suppurativa with cutaneous hyperpigmentation</td> </tr> <tr> <td>Presenilin enhancer, gamma-secretase subunit (<em>PSENEN</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/613736" target="_blank">613736</a></td> <td>Epidermis</td> <td>Notch signaling/gamma-secretase in hair follicle regulates keratinization</td> <td>Verneuil's disease/hidradenitis suppurativa</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Other IEI related to leukocytes</td> </tr> <tr> <td class="indent1">IRF4 haploinsufficiency</td> <td>Interferon regulatory factor 4 (<em>IRF4</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/601900" target="_blank">601900</a></td> <td>Lymphocytes, monocytes</td> <td>IRF4 is a pleiotropic transcription factor</td> <td>Whipple's disease</td> </tr> <tr> <td class="indent1">IL-18BP deficiency</td> <td>Interleukin 18 binding protein (<em>IL18BP</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/604113" target="_blank">604113</a></td> <td>Leukocytes and other cells</td> <td>IL-18BP neutralizes secreted IL-18</td> <td>Fulminant viral hepatitis</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of mutant genes in table: 74.</div><div class="graphic_footnotes">IUIS: International Union of Immunological Societies; 
    IL: interleukin; 
    AR: autosomal recessive; 
    NK: natural killer; 
    IFN: interferon; 
    AD: autosomal dominant; 
    LOF: loss of function; 
    XL: X linked; 
    cDC: conventional dendritic cell; 
    Th1: T helper type 1; 
    EBV: Epstein-Barr virus; 
    BCG: Bacillus Calmette-Guérin; 
    TNF: tumor necrosis factor; 
    MAIT: mucosal-associated invariant T; 
    iNKT: invariant natural killer T; 
    CD: cluster of differentiation; 
    HPV: human papillomavirus; 
    EVER: epidermodysplasia verruciformis; 
    GOF: gain of function; 
    CXCL12: C-X-C motif chemokine ligand 12; 
    SDF-1: stromal cell-derived factor 1; 
    ISGF3: interferon-stimulated gene factor 3 complex; 
    DC: dendritic cell; 
    HHV6: human herpesvirus 6; 
    VZV: varicella zoster virus; 
    MDA5: melanoma differentiation-associated gene 5; 
    RNA: ribonucleic acid; 
    CMV: cytomegalovirus; 
    HSV: herpes simplex virus; 
    ISG: interferon-stimulated gene; 
    DNA: deoxyribonucleic acid; 
    poly(I:C): polyinosinic-polycytidylic acid; 
    CNS: central nervous system; 
    TRIF: TIR domain-containing adaptor-inducing IFN-beta; 
    CMC: chronic mucocutaneous candidiasis; 
    ACT1: nuclear factor kappa B activator 1; 
    JNK1: JUN N-terminal kinase 1; 
    Th17: T helper type 17; 
    TGF: transforming growth factor; 
    ATF2: activating transcription factor 2; 
    TLR: toll-like receptor; 
    TIR: toll and interleukin 1 receptor; 
    MECP2: methyl-CpG binding protein 2; 
    COVID-19: coronavirus disease 2019; 
    IEI: inborn errors of immunity; 
    ER: endoplasmic reticulum.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright © 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 140002 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
